Vaccine

Oncovita receives FDA Orphan Drug Designation for its lead oncolytic virus candidate MVdeltaC in the treatment of pleural mesotheliomaOncovita receives FDA Orphan Drug Designation for its lead oncolytic virus candidate MVdeltaC in the treatment of pleural mesothelioma

Oncovita receives FDA Orphan Drug Designation for its lead oncolytic virus candidate MVdeltaC in the treatment of pleural mesothelioma

Oncovita receives FDA Orphan Drug Designation for its lead oncolytic virus candidate MVdeltaC in the treatment of pleural mesothelioma Paris,…

1 week ago
Conduit Pharmaceuticals Enters Joint Development Agreement with Manoira to Advance AZD1656 and AZD5658 in Animal HealthConduit Pharmaceuticals Enters Joint Development Agreement with Manoira to Advance AZD1656 and AZD5658 in Animal Health

Conduit Pharmaceuticals Enters Joint Development Agreement with Manoira to Advance AZD1656 and AZD5658 in Animal Health

Collaboration leverages cutting-edge reformulation expertise to generate cross-species insights, fast-track human clinical programs, and seeks to capture commercial potential in…

1 week ago
Elicio Therapeutics Secures $10 Million in FinancingElicio Therapeutics Secures $10 Million in Financing

Elicio Therapeutics Secures $10 Million in Financing

Funding expected to support operations into Q1 2026. Anticipated AMPLIFY-7P Phase 2 interim analysis expected in Q3 2025. BOSTON, June…

1 week ago
Sharps Technology Begins Shipments Across Three Customer Orders Under Previously Announced Purchase AgreementsSharps Technology Begins Shipments Across Three Customer Orders Under Previously Announced Purchase Agreements

Sharps Technology Begins Shipments Across Three Customer Orders Under Previously Announced Purchase Agreements

Shipments include initial deliveries of SecureGard™ and SoloGard™ smart safety syringes from its Hungary-based manufacturing facility Deliveries mark the Company’s…

1 week ago
OSE Immunotherapeutics strengthens Growth Strategy:  Accelerates key pillars of Inflammation and Immuno-OncologyOSE Immunotherapeutics strengthens Growth Strategy:  Accelerates key pillars of Inflammation and Immuno-Oncology

OSE Immunotherapeutics strengthens Growth Strategy: Accelerates key pillars of Inflammation and Immuno-Oncology

Figure_1 Figure 1: Clinical Remission rate observed in all-comers population and sub-population according to composite IL7R axis biomarker in CoTikiS…

1 week ago
Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate UpdateValneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update

Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update

Saint-Herblain (France), June 4, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company (“the Company”), today…

1 week ago
FSA Store® Issues Alert for June 30 flexible spending account (FSA) Spending Deadline: Check Your Balance and Use, Don’t Lose, Tax-free FundsFSA Store® Issues Alert for June 30 flexible spending account (FSA) Spending Deadline: Check Your Balance and Use, Don’t Lose, Tax-free Funds

FSA Store® Issues Alert for June 30 flexible spending account (FSA) Spending Deadline: Check Your Balance and Use, Don’t Lose, Tax-free Funds

FSA Store recommends three steps to help account holders avoid forfeiting unused funds to the June 30 deadline – a…

1 week ago
Press Release:  ASCO: new Sarclisa data support subcutaneous administration with on-body injectorPress Release:  ASCO: new Sarclisa data support subcutaneous administration with on-body injector

Press Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector

ASCO: new Sarclisa data support subcutaneous administration with on-body injector New data from two clinical studies demonstrated that Sarclisa administered…

1 week ago
IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 StudyIMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study

IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study

Consistent OS Efficacy Benefit Across Multiple Treatment Subgroups Demonstrates IMNN-001’s Ability to Recruit a Powerful Anti-Cancer Immune Response  Results, presented…

1 week ago
Rapid Dose Announces Completion of Share Issuance in Debt Settlement with CreditorsRapid Dose Announces Completion of Share Issuance in Debt Settlement with Creditors

Rapid Dose Announces Completion of Share Issuance in Debt Settlement with Creditors

Burlington, Ontario--(Newsfile Corp. - June 2, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") today announced…

1 week ago